TRP2-electroporated autologous dendritic cell therapy (Memorial Sloan-Kettering)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTRP2-electroporated autologous dendritic cell therapy (Memorial Sloan-Kettering)
Drug Alias Nameautologous langerhans-type dendritic cell therapy (TRP2-electroporated) (Memorial Sloan-Kettering)
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine +[4] 
Mechanisms of ActionMacrophage migration inhibitory factor modulators
TargetsMacrophage migration inhibitory factor
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A